From:  Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study

Reasons for transition

Cause    Indication
    RA (n = 73)
    n    %
Mandated by health authority/payer    2    2.7
Cost    32    43.8
Adverse event    0    0.0
Patient decision    0    0.0
Physician decision    37    50.7
Other    2    2.7
Total    73    100.0
Return to article view

RA: rheumatoid arthritis